Avenue Therapeutics, INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
OID
Avenue Therapeutics reported a net loss of $0.7 million for Q1 2026, a significant improvement from the prior year, as the company advances its ATX-04 and IV tramadol programs.
OID
Avenue Therapeutics reports significant net loss reduction in Q3 2025, driven by asset sales and cost cuts, amidst Nasdaq delisting and going concern doubts.
OID
Avenue Therapeutics reports Q2 2025 results, including revenue from AnnJi license termination and a net income attributable to Avenue.
OID
Avenue Therapeutics reported its Q1 2025 financial results, detailing a net loss reduction, Nasdaq delisting, and the termination of the AnnJi License Agreement.
OID
Avenue Therapeutics reported a net loss of $3.1 million for the third quarter of 2024, while advancing its clinical programs for AJ201, IV tramadol, and BAER-101.
OID
Avenue Therapeutics reported its Q2 2024 financial results, noting a net loss but also highlighting advancements in its clinical programs and recent capital raising activities.
OID
Avenue Therapeutics reported a net loss of $4.3 million for Q1 2024 and faces substantial doubt about its ability to continue as a going concern.